Literature DB >> 26075856

[Combination treatment of hypertension in 2015].

Jindřich Špinar, Jiří Vítovec, Lenka Špinarová, Miroslava Bendová.   

Abstract

We present an overview of the present views on combination treatment and on fixed combinations in the treatment of hypertension according to guidelines of ESH/ESC and ČSH from 2013. The most frequently recommended dual combinations include a blocker of the renin-angiotensin system (ACEI or sartan) and a calcium channel blocker, and further a blocker of the renin-angiotensin system and a diuretic and a calcium channel blocker and a diuretic. In 2014 a fixed-dose combination of an ACE inhibitor (perindopril), a calcium channel blocker (amlodipine) and an diuretic (indapamide) appeared on the Czech market. Within the PIANIST study including 4 731 insufficiently controlled hypertensives, a fixed-dose triple combination of perindopril, amlodipine and indapamide led to a decrease in blood pressure by 28.3/13.8 mm Hg and to a sufficient control of hypertension in 92 % of patients. The advantage of fixed combinations primarily consists in greater compliance of patients and thereby in a better control of hypertension. About 1/3 of hypertensives need a triple combination for a satisfactory blood pressure control.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26075856

Source DB:  PubMed          Journal:  Vnitr Lek        ISSN: 0042-773X


  2 in total

1.  MiR-20b-5p contributes to the dysfunction of vascular smooth muscle cells by targeting MAGI3 in hypertension.

Authors:  Minzhi Xu; Ting Yu
Journal:  J Mol Histol       Date:  2022-01-05       Impact factor: 2.611

2.  UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015.

Authors:  Kenan Selmanovic; Svjetlana Loga Zec; Nenad Vanis; Lamija Zecevic; Manja Setkic; Azra Rasic; Enver Zerem
Journal:  Mater Sociomed       Date:  2016-03-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.